Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease

This study is ongoing, but not recruiting participants.

Study NCT00528073 Information provided by Alfa Wassermann S.p.A.

First Received: September 10, 2007 Last Updated: April 20, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	October 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)